Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
5d
Pharmaceutical Technology on MSNSupernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...
Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.
Trump’s “first buddy” Elon Musk made a lively, chaotic and unpredictable appearance at the Conservative Political Action ...
Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results